A concise review on anti-breast cancer effectiveness of s-triazines through EGFR kinase inhibition
Today, one of the most common malignancies in women is breast cancer. Despite the large number of commercially available anticancer drugs, cancer cannot be cured without leaving adverse effects. The MCF-7, a human breast cancer cell line, has been the subject of the most research globally. Similarly...
Saved in:
| Published in | Medicinal chemistry research Vol. 33; no. 1; pp. 47 - 65 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
New York
Springer US
01.01.2024
Springer Nature B.V |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1054-2523 1554-8120 |
| DOI | 10.1007/s00044-023-03180-1 |
Cover
| Abstract | Today, one of the most common malignancies in women is breast cancer. Despite the large number of commercially available anticancer drugs, cancer cannot be cured without leaving adverse effects. The MCF-7, a human breast cancer cell line, has been the subject of the most research globally. Similarly, overexpression of the EGFR protein increases cell proliferation and decreases cell death or apoptosis. This can stimulate several downstream signaling pathways. Therefore, novel drugs against cancer with improved selectivity and specificity are required to overcome the limitations of present therapy. The
s
-triazine derivatives have been designed and developed to exhibit excellent anticancer effects on the MCF-7 cell line and demonstrate enzymatic activity by blocking the EGFR via the PI3K/AKT/mTOR signaling pathways. Therefore, the major goal of this in-depth study is to analyze and summarize the literature on recent developments in
s
-triazine-based heterocycles and their anti-breast cancer potential with structure-activity relationships (SAR). |
|---|---|
| AbstractList | Today, one of the most common malignancies in women is breast cancer. Despite the large number of commercially available anticancer drugs, cancer cannot be cured without leaving adverse effects. The MCF-7, a human breast cancer cell line, has been the subject of the most research globally. Similarly, overexpression of the EGFR protein increases cell proliferation and decreases cell death or apoptosis. This can stimulate several downstream signaling pathways. Therefore, novel drugs against cancer with improved selectivity and specificity are required to overcome the limitations of present therapy. The s-triazine derivatives have been designed and developed to exhibit excellent anticancer effects on the MCF-7 cell line and demonstrate enzymatic activity by blocking the EGFR via the PI3K/AKT/mTOR signaling pathways. Therefore, the major goal of this in-depth study is to analyze and summarize the literature on recent developments in s-triazine-based heterocycles and their anti-breast cancer potential with structure-activity relationships (SAR). Today, one of the most common malignancies in women is breast cancer. Despite the large number of commercially available anticancer drugs, cancer cannot be cured without leaving adverse effects. The MCF-7, a human breast cancer cell line, has been the subject of the most research globally. Similarly, overexpression of the EGFR protein increases cell proliferation and decreases cell death or apoptosis. This can stimulate several downstream signaling pathways. Therefore, novel drugs against cancer with improved selectivity and specificity are required to overcome the limitations of present therapy. The s -triazine derivatives have been designed and developed to exhibit excellent anticancer effects on the MCF-7 cell line and demonstrate enzymatic activity by blocking the EGFR via the PI3K/AKT/mTOR signaling pathways. Therefore, the major goal of this in-depth study is to analyze and summarize the literature on recent developments in s -triazine-based heterocycles and their anti-breast cancer potential with structure-activity relationships (SAR). |
| Author | Upadhyay, Rachana Tandel, Pooja Patel, Amit B. |
| Author_xml | – sequence: 1 givenname: Pooja surname: Tandel fullname: Tandel, Pooja organization: Department of Chemistry, Government College, Daman (Affiliated to Veer Narmad South Gujarat University, Surat) – sequence: 2 givenname: Rachana surname: Upadhyay fullname: Upadhyay, Rachana organization: Department of Chemistry, Government College, Daman (Affiliated to Veer Narmad South Gujarat University, Surat) – sequence: 3 givenname: Amit B. orcidid: 0000-0002-5236-0038 surname: Patel fullname: Patel, Amit B. email: amit.svnit10@gmail.com organization: Department of Chemistry, Government College, Daman (Affiliated to Veer Narmad South Gujarat University, Surat) |
| BookMark | eNp9kF9LXDEQxUNRqP--gE-BPkdnktzNvY8iaguCUNrnkJuduNnaxCbZLfrpG11B6INPcwbOb-ZwDtleyokYO0U4QwBzXgFAawFSCVA4gsBP7ACHQYsRJex1DV3LQarP7LDWNYAyoIcDNl9wn5OPlXihbaS_PCfuUotiLuRq494lT4VTCORb3FKiWnkOvIpWonuOfedtVfLmfsWvbq6_818xuX4tplWcY4s5HbP94B4qnbzNI_bz-urH5Vdxe3fz7fLiVniFUxO0mIIZVEDtcJKLSQ1Ls8DlFHwISPOkyIGalYcRjZbDaLQ2fjbLcall8J08Yl92dx9L_rOh2uw6b0rqL62cUCGaARfdNe5cvuRaCwXrY3MvOVtx8cEi2JdG7a5R2xu1r41a7Kj8D30s8bcrTx9DagfVbk73VN5TfUD9AyuMimY |
| CitedBy_id | crossref_primary_10_1002_slct_202402766 |
| Cites_doi | 10.1177/1747519820904844 10.3389/fonc.2014.00221 10.3390/pharmaceutics14081558 10.1016/j.ceb.2005.02.010 10.2174/1568026620666200310122741 10.1016/j.bioorg.2022.106263 10.1021/ja075523m 10.1002/mco2.163 10.1002/ijc.33588 10.1021/acsomega.1c06836 10.1016/j.bioorg.2019.103525 10.1016/j.ejmech.2020.112637 10.1016/j.bmc.2021.115997 10.1097/01.cad.0000173476.67239.3b 10.1016/j.ajpath.2017.04.007 10.1016/j.bbalip.2014.12.006 10.1039/C3NP70058E 10.1039/D0RA06799G 10.1016/j.bmcl.2015.02.067 10.1080/13543776.2021.1860210 10.3892/mmr.2018.9426 10.3389/fchem.2022.1078163 10.1038/s41598-017-05934-5 10.1002/jhet.3791 10.2174/1389557520666200729160720 10.1002/cncr.28057 10.1002/jhet.4470 10.1016/j.biopha.2022.113537 10.1002/cmdc.202000646 10.1016/j.molonc.2010.04.006 10.1021/acsomega.2c03079 10.1016/j.gendis.2018.04.001 10.1016/j.bioorg.2022.106157 10.1007/s00428-008-0665-y 10.1039/D1NJ02419A 10.1002/slct.202301053 10.1172/JCI73939 10.1155/2022/5918686 10.2174/1570193X18666210225115511 10.4155/fmc-2018-0145 10.1007/s11523-010-0140-y |
| ContentType | Journal Article |
| Copyright | The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
| Copyright_xml | – notice: The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
| DBID | AAYXX CITATION 8FD FR3 M7Z P64 |
| DOI | 10.1007/s00044-023-03180-1 |
| DatabaseName | CrossRef Technology Research Database Engineering Research Database Biochemistry Abstracts 1 Biotechnology and BioEngineering Abstracts |
| DatabaseTitle | CrossRef Biochemistry Abstracts 1 Engineering Research Database Technology Research Database Biotechnology and BioEngineering Abstracts |
| DatabaseTitleList | Biochemistry Abstracts 1 |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1554-8120 |
| EndPage | 65 |
| ExternalDocumentID | 10_1007_s00044_023_03180_1 |
| GroupedDBID | --- -56 -5G -BR -EM -Y2 -~C .86 .GJ .VR 06C 06D 0R~ 0VY 1N0 203 29M 29~ 2J2 2JN 2JY 2KG 2LR 2VQ 2~H 30V 4.4 406 408 409 40D 40E 5GY 5VS 67N 67Z 6NX 78A 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABJNI ABJOX ABKCH ABKTR ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTHY ABTKH ABTMW ABULA ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHXU ACIWK ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACSNA ACZOJ ADHHG ADHIR ADINQ ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFFNX AFGCZ AFLOW AFQWF AFWTZ AFZKB AGAYW AGDGC AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHKAY AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BAPOH BDATZ BGNMA BSONS CAG COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 EBLON EBS EIOEI EJD EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GXS H13 HF~ HG5 HG6 HLICF HMJXF HQYDN HRMNR HVGLF HZ~ IHE IJ- IKXTQ IWAJR IXC IXD IXE IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KPH LAS LLZTM M4Y MA- N2Q NB0 NPVJJ NQJWS NU0 O9- O93 O9I O9J OAM P2P PF0 PT4 QOR QOS R89 R9I RIG ROL RPX RSV S16 S1Z S27 S3A S3B SAP SBL SDH SHX SISQX SJYHP SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SZN T13 TSG TSK TSV TUC U2A U9L UG4 UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WK8 YLTOR Z45 Z7U Z7V Z87 ZMTXR ZOVNA ~A9 ~KM AAPKM AAYXX ABBRH ABDBE ABFSG ACSTC ADHKG AEZWR AFDZB AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION 8FD ABRTQ FR3 M7Z P64 |
| ID | FETCH-LOGICAL-c319t-e69f753f14a1926935d761d9fcff1eb93ea03b3c081742587447cb7d8d42fc753 |
| IEDL.DBID | AGYKE |
| ISSN | 1054-2523 |
| IngestDate | Fri Jul 25 10:58:39 EDT 2025 Tue Jul 01 01:53:36 EDT 2025 Thu Apr 24 22:57:48 EDT 2025 Fri Feb 21 02:41:35 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Structure-activity relationships (SAR) Signaling pathway Anti-breast cancer MCF-7 EGFR triazine |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c319t-e69f753f14a1926935d761d9fcff1eb93ea03b3c081742587447cb7d8d42fc753 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 |
| ORCID | 0000-0002-5236-0038 |
| PQID | 2913117516 |
| PQPubID | 2043723 |
| PageCount | 19 |
| ParticipantIDs | proquest_journals_2913117516 crossref_citationtrail_10_1007_s00044_023_03180_1 crossref_primary_10_1007_s00044_023_03180_1 springer_journals_10_1007_s00044_023_03180_1 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20240100 2024-01-00 20240101 |
| PublicationDateYYYYMMDD | 2024-01-01 |
| PublicationDate_xml | – month: 1 year: 2024 text: 20240100 |
| PublicationDecade | 2020 |
| PublicationPlace | New York |
| PublicationPlace_xml | – name: New York – name: Heidelberg |
| PublicationTitle | Medicinal chemistry research |
| PublicationTitleAbbrev | Med Chem Res |
| PublicationYear | 2024 |
| Publisher | Springer US Springer Nature B.V |
| Publisher_xml | – name: Springer US – name: Springer Nature B.V |
| References | van Krieken, Jung, Kirchner, Carneiro, Seruca, Bosman (CR13) 2008; 453 Shawish, Barakat, Aldalbahi, Alshaer, Daoud, Alqudah (CR34) 2022; 14 Nasir, Ghazal, Khan, Zubair, Rahman, Ahmed (CR5) 2022; 2022 Kushwaha, Sharma (CR18) 2021; 20 Li, Wu, Zhou, Zhu (CR3) 2018; 5 Morgensztern, McLeod (CR9) 2005; 16 Raghu, Pradeep Kumar, Prashanth, Yogesh Kumar, Prathibha, Kanthimathi (CR30) 2021; 45 Sun, Zhang, Luo, Yang, He, Zhang (CR42) 2022; 129 Moreno, Quiroga, Abonia, Lauria, Martorana, Insuasty (CR29) 2020; 10 Spicer, Rudman (CR14) 2010; 5 Shawish, Nafie, Barakat, Aldalbahi, Al-Rasheed, Ali (CR32) 2022; 10 Zhu, Zhang, Yu, Wang, Cheng (CR20) 2008; 130 Leung, Kim, Askarian-Amiri, Joseph, McKeage, Baguley (CR23) 2014; 4 Hashem, Amr, Nossier, Anwar, Azmy (CR31) 2022; 7 Ferlay, Colombet, Soerjomataram, Parkin, Piñeros, Znaor (CR1) 2021; 149 Yan, Zhao, He (CR26) 2018; 18 Wang, Shen, Zhang, Hei, Zhao, Xin (CR36) 2018; 10 Xu, Sun, Luo, Yang, Guo, Tang (CR41) 2022; 155 Sun, Xu, Yang, Zheng, Zhu (CR15) 2021; 31 Xiao, Zhu, Wu, Ma, Qi, Ha (CR24) 2023; 130 CR4 Hawkins, Stephens (CR10) 2015; 1851 Pathak, Rimac, Grishina, Verma, Potemkin (CR28) 2021; 16 Woodgett (CR11) 2005; 17 Bauer, Brönstrup (CR16) 2014; 31 Shawish, Barakat, Aldalbahi, Malebari, Nafie, Bekhit (CR33) 2022; 7 Wu, Guo, Chen, Wang, Du, Chen (CR38) 2020; 204 Shukla, Maiti (CR17) 2022; 3 Zhang, Zhang, Xiao, Sun, Yang, Gu (CR37) 2020; 95 Podo, Buydens, Degani, Hilhorst, Klipp, Gribbestad (CR6) 2010; 4 Romito, Goldzweig, Cormio, Hagedoorn, Andersen (CR2) 2013; 119 Guo, Zhang, Wang, Pei, Sun, Zhang (CR8) 2017; 187 Kumari, Singh (CR22) 2022; 19 Sahin, Biltekin, Ozansoy, Hemiş, Ozansoy, Yurttaş (CR19) 2022; 59 Bhat, Masih, Shakya, Ghosh, Singh (CR27) 2020; 57 Xin, Wang, Zhang, Shen, Zhang (CR39) 2020; 44 Srivastava, Pillai, Bhat, Verma, Singh (CR25) 2017; 7 Guo, Diao (CR21) 2020; 20 Hu, Zhang, Tang, Lu, Guo, Huang (CR40) 2021; 32 Kim, Guan (CR12) 2015; 125 Wang, Xu, Xin, Lu, Zhang (CR35) 2015; 25 Patel, Mistry, Gujarati, Patel, Patel (CR7) 2023; 8 F Romito (3180_CR2) 2013; 119 M Xiao (3180_CR24) 2023; 130 Z Sahin (3180_CR19) 2022; 59 Y-C Guo (3180_CR8) 2017; 187 I Shawish (3180_CR32) 2022; 10 JF Spicer (3180_CR14) 2010; 5 LM Moreno (3180_CR29) 2020; 10 M Xin (3180_CR39) 2020; 44 T-T Wu (3180_CR38) 2020; 204 X Sun (3180_CR42) 2022; 129 A Bauer (3180_CR16) 2014; 31 F Podo (3180_CR6) 2010; 4 EY Leung (3180_CR23) 2014; 4 F Li (3180_CR3) 2018; 5 B Zhang (3180_CR37) 2020; 95 X-Q Zhu (3180_CR20) 2008; 130 P Pathak (3180_CR28) 2021; 16 S Xu (3180_CR41) 2022; 155 J Ferlay (3180_CR1) 2021; 149 YC Kim (3180_CR12) 2015; 125 HR Bhat (3180_CR27) 2020; 57 JR Woodgett (3180_CR11) 2005; 17 I Shawish (3180_CR34) 2022; 14 S Kumari (3180_CR22) 2022; 19 JK Srivastava (3180_CR25) 2017; 7 N Kushwaha (3180_CR18) 2021; 20 W Yan (3180_CR26) 2018; 18 RV Patel (3180_CR7) 2023; 8 H Guo (3180_CR21) 2020; 20 I Shawish (3180_CR33) 2022; 7 PT Hawkins (3180_CR10) 2015; 1851 H-Y Wang (3180_CR36) 2018; 10 X Sun (3180_CR15) 2021; 31 MS Raghu (3180_CR30) 2021; 45 HE Hashem (3180_CR31) 2022; 7 3180_CR4 D Morgensztern (3180_CR9) 2005; 16 A Shukla (3180_CR17) 2022; 3 X-M Wang (3180_CR35) 2015; 25 MU Nasir (3180_CR5) 2022; 2022 J Hu (3180_CR40) 2021; 32 JHJM van Krieken (3180_CR13) 2008; 453 |
| References_xml | – volume: 44 start-page: 393 year: 2020 end-page: 402 ident: CR39 article-title: Synthesis and biological activity of new 2,4,6-trisubstituted triazines as potential phosphoinositide 3-kinase inhibitors publication-title: J Chem Res doi: 10.1177/1747519820904844 – volume: 4 start-page: 1 year: 2014 end-page: 9 ident: CR23 article-title: Hormone resistance in two MCF-7 breast cancer cell lines is associated with reduced mtor signaling, decreased glycolysis, and increased sensitivity to cytotoxic drugs publication-title: Front Oncol doi: 10.3389/fonc.2014.00221 – volume: 14 start-page: 1558 year: 2022 ident: CR34 article-title: Acetic acid mediated for one-pot synthesis of novel pyrazolyl s-triazine derivatives for the targeted therapy of triple-negative breast tumor cells (MDA-MB-231) via EGFR/PI3K/AKT/mTOR signaling cascades publication-title: Pharmaceutics doi: 10.3390/pharmaceutics14081558 – volume: 17 start-page: 150 year: 2005 end-page: 7 ident: CR11 article-title: Recent advances in the protein kinase B signaling pathway publication-title: Curr Opin Cell Biol doi: 10.1016/j.ceb.2005.02.010 – volume: 20 start-page: 1481 year: 2020 end-page: 92 ident: CR21 article-title: 1,3,5-Triazine-azole hybrids and their anticancer activity publication-title: Curr Top Med Chem doi: 10.2174/1568026620666200310122741 – volume: 130 start-page: 106263 year: 2023 ident: CR24 article-title: Novel 6-amino-1,3,5-triazine derivatives as potent BTK inhibitors: structure-activity relationship (SAR) analysis and preliminary mechanism investigation publication-title: Bioorg Chem doi: 10.1016/j.bioorg.2022.106263 – volume: 130 start-page: 2501 year: 2008 end-page: 16 ident: CR20 article-title: Hydride, hydrogen atom, proton, and electron transfer driving forces of various five-membered heterocyclic organic hydrides and their reaction intermediates in acetonitrile publication-title: J Am Chem Soc doi: 10.1021/ja075523m – volume: 3 start-page: 1 year: 2022 end-page: 31 ident: CR17 article-title: Nanomedicine and versatile therapies for cancer treatment publication-title: MedComm doi: 10.1002/mco2.163 – volume: 149 start-page: 778 year: 2021 end-page: 89 ident: CR1 article-title: Cancer statistics for the year 2020: an overview publication-title: Int J Cancer doi: 10.1002/ijc.33588 – ident: CR4 – volume: 7 start-page: 7155 year: 2022 end-page: 71 ident: CR31 article-title: New benzimidazole-, 1,2,4-triazole-, and 1,3,5-triazine-based derivatives as potential EGFR and EGFR inhibitors: microwave-assisted synthesis, anticancer evaluation, and molecular docking study publication-title: ACS Omega doi: 10.1021/acsomega.1c06836 – volume: 95 start-page: 103525 year: 2020 ident: CR37 article-title: Design, synthesis and biological evaluation of substituted 2-(thiophen-2-yl)-1,3,5-triazine derivatives as potential dual PI3Kα/mTOR inhibitors publication-title: Bioorg Chem doi: 10.1016/j.bioorg.2019.103525 – volume: 204 start-page: 112637 year: 2020 ident: CR38 article-title: Design, synthesis and bioevaluation of novel substituted triazines as potential dual PI3K/mTOR inhibitors publication-title: Eur J Med Chem doi: 10.1016/j.ejmech.2020.112637 – volume: 32 start-page: 115997 year: 2021 ident: CR40 article-title: Discovery of novel 1,3,5-triazine derivatives as potent inhibitor of cervical cancer via dual inhibition of PI3K/mTOR publication-title: Bioorg Med Chem doi: 10.1016/j.bmc.2021.115997 – volume: 16 start-page: 797 year: 2005 end-page: 803 ident: CR9 article-title: PI3K/Akt/mTOR pathway as a target for cancer therapy publication-title: Anticancer Drugs doi: 10.1097/01.cad.0000173476.67239.3b – volume: 187 start-page: 1736 year: 2017 end-page: 49 ident: CR8 article-title: Macrophages regulate unilateral ureteral obstruction-induced renal lymphangiogenesis through C-C motif chemokine receptor 2–dependent phosphatidylinositol 3-kinase-AKT–mechanistic target of rapamycin signaling and hypoxia-inducible factor-1α/vascular endothelial growth factor-C expression publication-title: Am J Pathol doi: 10.1016/j.ajpath.2017.04.007 – volume: 1851 start-page: 882 year: 2015 end-page: 97 ident: CR10 article-title: PI3K signalling in inflammation publication-title: Biochim Biophys Acta Mol Cell Biol Lipids doi: 10.1016/j.bbalip.2014.12.006 – volume: 31 start-page: 35 year: 2014 end-page: 60 ident: CR16 article-title: Industrial natural product chemistry for drug discovery and development publication-title: Nat Prod Rep doi: 10.1039/C3NP70058E – volume: 10 start-page: 34114 year: 2020 end-page: 29 ident: CR29 article-title: Synthesis, biological evaluation, and in silico studies of novel chalcone- and pyrazoline-based 1,3,5-triazines as potential anticancer agents publication-title: RSC Adv doi: 10.1039/D0RA06799G – volume: 25 start-page: 1730 year: 2015 end-page: 5 ident: CR35 article-title: Design, synthesis and antiproliferative activity evaluation of m -(4-morpholinyl-1,3,5-triazin-2-yl)benzamides in vitro publication-title: Bioorg Med Chem Lett doi: 10.1016/j.bmcl.2015.02.067 – volume: 31 start-page: 223 year: 2021 end-page: 38 ident: CR15 article-title: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: a patent review (2014-present) publication-title: Expert Opin Ther Pat doi: 10.1080/13543776.2021.1860210 – volume: 18 start-page: 4175 year: 2018 end-page: 84 ident: CR26 article-title: Anti-breast cancer activity of selected 1,3,5-triazines via modulation of EGFR-TK publication-title: Mol Med Rep doi: 10.3892/mmr.2018.9426 – volume: 10 start-page: 1 year: 2022 end-page: 19 ident: CR32 article-title: Pyrazolyl-s-triazine with indole motif as a novel of epidermal growth factor receptor/cyclin-dependent kinase 2 dual inhibitors publication-title: Front Chem doi: 10.3389/fchem.2022.1078163 – volume: 7 year: 2017 ident: CR25 article-title: Design and discovery of novel monastrol-1,3,5-triazines as potent anti-breast cancer agent via attenuating Epidermal Growth Factor Receptor tyrosine kinase publication-title: Sci Rep doi: 10.1038/s41598-017-05934-5 – volume: 57 start-page: 390 year: 2020 end-page: 9 ident: CR27 article-title: Design, synthesis, anticancer, antibacterial, and antifungal evaluation of 4‐aminoquinoline‐1,3,5‐triazine derivatives publication-title: J Heterocycl Chem doi: 10.1002/jhet.3791 – volume: 20 start-page: 2104 year: 2021 end-page: 22 ident: CR18 article-title: The chemistry of triazine isomers: structures, reactions, synthesis and applications publication-title: Mini Rev Med Chem doi: 10.2174/1389557520666200729160720 – volume: 119 start-page: 2160 year: 2013 end-page: 9 ident: CR2 article-title: Informal caregiving for cancer patients publication-title: Cancer doi: 10.1002/cncr.28057 – volume: 59 start-page: 1333 year: 2022 end-page: 40 ident: CR19 article-title: Synthesis and in vitro antitumor activities of novel thioamide substituted piperazinyl‐1,2, 4‐triazines publication-title: J Heterocycl Chem doi: 10.1002/jhet.4470 – volume: 155 start-page: 113537 year: 2022 ident: CR41 article-title: XS-2, a novel potent dual PI3K/mTOR inhibitor, exhibits high in vitro and in vivo anti-breast cancer activity and low toxicity with the potential to inhibit the invasion and migration of triple-negative breast cancer publication-title: Biomed Pharmacother doi: 10.1016/j.biopha.2022.113537 – volume: 16 start-page: 822 year: 2021 end-page: 38 ident: CR28 article-title: Hybrid quinazoline 1,3,5‐triazines as epidermal growth factor receptor (EGFR) inhibitors with anticancer activity: design, synthesis, and computational study publication-title: ChemMedChem doi: 10.1002/cmdc.202000646 – volume: 4 start-page: 209 year: 2010 end-page: 29 ident: CR6 article-title: Triple-negative breast cancer: present challenges and new perspectives publication-title: Mol Oncol doi: 10.1016/j.molonc.2010.04.006 – volume: 7 start-page: 24858 year: 2022 end-page: 70 ident: CR33 article-title: Synthesis and antiproliferative activity of a new series of mono- and bis(dimethylpyrazolyl)- -triazine derivatives targeting EGFR/PI3K/AKT/mTOR signaling cascades publication-title: ACS Omega doi: 10.1021/acsomega.2c03079 – volume: 5 start-page: 75 year: 2018 end-page: 76 ident: CR3 article-title: Clonal hematopoiesis of indeterminate potential (CHIP): a potential contributor to atherlosclerotic cardio/cerebro-vascular diseases? publication-title: Genes Dis doi: 10.1016/j.gendis.2018.04.001 – volume: 129 start-page: 106157 year: 2022 ident: CR42 article-title: Design, synthesis and pharmacological evaluation of 2-arylurea-1,3,5-triazine derivative (XIN-9): a novel potent dual PI3K/mTOR inhibitor for cancer therapy publication-title: Bioorg Chem doi: 10.1016/j.bioorg.2022.106157 – volume: 453 start-page: 417 year: 2008 end-page: 31 ident: CR13 article-title: KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program publication-title: Virchows Arch doi: 10.1007/s00428-008-0665-y – volume: 45 start-page: 13909 year: 2021 end-page: 24 ident: CR30 article-title: Novel 1,3,5-triazine-based pyrazole derivatives as potential antitumor agents and EFGR kinase inhibitors: synthesis, cytotoxicity, DNA binding, molecular docking and DFT studies publication-title: N. J Chem doi: 10.1039/D1NJ02419A – volume: 8 start-page: 1 year: 2023 end-page: 28 ident: CR7 article-title: Epidermal growth factor receptor inhibiting 4‐aminoquinazolines as promising anticancer agents: a patent review (2000‐Present) publication-title: ChemistrySelect doi: 10.1002/slct.202301053 – volume: 125 start-page: 25 year: 2015 end-page: 32 ident: CR12 article-title: mTOR: a pharmacologic target for autophagy regulation publication-title: J Clin Investig doi: 10.1172/JCI73939 – volume: 2022 start-page: 1 year: 2022 end-page: 9 ident: CR5 article-title: Breast cancer prediction empowered with fine-tuning publication-title: Comput Intell Neurosci doi: 10.1155/2022/5918686 – volume: 19 start-page: 52 year: 2022 end-page: 65 ident: CR22 article-title: Various techniques for one-pot synthesis of 1,3,5-triazine (s-Triazine) derivatives: a review publication-title: Mini Rev Org Chem doi: 10.2174/1570193X18666210225115511 – volume: 10 start-page: 2445 year: 2018 end-page: 55 ident: CR36 article-title: Discovery of 2-(aminopyrimidin-5-yl)-4-(morpholin-4-yl)-6- substituted triazine as PI3K and BRAF dual inhibitor publication-title: Future Med Chem doi: 10.4155/fmc-2018-0145 – volume: 5 start-page: 245 year: 2010 end-page: 55 ident: CR14 article-title: EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992 publication-title: Target Oncol doi: 10.1007/s11523-010-0140-y – volume: 204 start-page: 112637 year: 2020 ident: 3180_CR38 publication-title: Eur J Med Chem doi: 10.1016/j.ejmech.2020.112637 – volume: 95 start-page: 103525 year: 2020 ident: 3180_CR37 publication-title: Bioorg Chem doi: 10.1016/j.bioorg.2019.103525 – volume: 19 start-page: 52 year: 2022 ident: 3180_CR22 publication-title: Mini Rev Org Chem doi: 10.2174/1570193X18666210225115511 – volume: 44 start-page: 393 year: 2020 ident: 3180_CR39 publication-title: J Chem Res doi: 10.1177/1747519820904844 – volume: 125 start-page: 25 year: 2015 ident: 3180_CR12 publication-title: J Clin Investig doi: 10.1172/JCI73939 – volume: 10 start-page: 34114 year: 2020 ident: 3180_CR29 publication-title: RSC Adv doi: 10.1039/D0RA06799G – volume: 149 start-page: 778 year: 2021 ident: 3180_CR1 publication-title: Int J Cancer doi: 10.1002/ijc.33588 – ident: 3180_CR4 – volume: 20 start-page: 1481 year: 2020 ident: 3180_CR21 publication-title: Curr Top Med Chem doi: 10.2174/1568026620666200310122741 – volume: 453 start-page: 417 year: 2008 ident: 3180_CR13 publication-title: Virchows Arch doi: 10.1007/s00428-008-0665-y – volume: 10 start-page: 2445 year: 2018 ident: 3180_CR36 publication-title: Future Med Chem doi: 10.4155/fmc-2018-0145 – volume: 2022 start-page: 1 year: 2022 ident: 3180_CR5 publication-title: Comput Intell Neurosci doi: 10.1155/2022/5918686 – volume: 59 start-page: 1333 year: 2022 ident: 3180_CR19 publication-title: J Heterocycl Chem doi: 10.1002/jhet.4470 – volume: 8 start-page: 1 year: 2023 ident: 3180_CR7 publication-title: ChemistrySelect doi: 10.1002/slct.202301053 – volume: 10 start-page: 1 year: 2022 ident: 3180_CR32 publication-title: Front Chem doi: 10.3389/fchem.2022.1078163 – volume: 45 start-page: 13909 year: 2021 ident: 3180_CR30 publication-title: N. J Chem doi: 10.1039/D1NJ02419A – volume: 32 start-page: 115997 year: 2021 ident: 3180_CR40 publication-title: Bioorg Med Chem doi: 10.1016/j.bmc.2021.115997 – volume: 1851 start-page: 882 year: 2015 ident: 3180_CR10 publication-title: Biochim Biophys Acta Mol Cell Biol Lipids doi: 10.1016/j.bbalip.2014.12.006 – volume: 4 start-page: 1 year: 2014 ident: 3180_CR23 publication-title: Front Oncol doi: 10.3389/fonc.2014.00221 – volume: 20 start-page: 2104 year: 2021 ident: 3180_CR18 publication-title: Mini Rev Med Chem doi: 10.2174/1389557520666200729160720 – volume: 17 start-page: 150 year: 2005 ident: 3180_CR11 publication-title: Curr Opin Cell Biol doi: 10.1016/j.ceb.2005.02.010 – volume: 31 start-page: 223 year: 2021 ident: 3180_CR15 publication-title: Expert Opin Ther Pat doi: 10.1080/13543776.2021.1860210 – volume: 14 start-page: 1558 year: 2022 ident: 3180_CR34 publication-title: Pharmaceutics doi: 10.3390/pharmaceutics14081558 – volume: 16 start-page: 822 year: 2021 ident: 3180_CR28 publication-title: ChemMedChem doi: 10.1002/cmdc.202000646 – volume: 5 start-page: 75 year: 2018 ident: 3180_CR3 publication-title: Genes Dis doi: 10.1016/j.gendis.2018.04.001 – volume: 18 start-page: 4175 year: 2018 ident: 3180_CR26 publication-title: Mol Med Rep doi: 10.3892/mmr.2018.9426 – volume: 4 start-page: 209 year: 2010 ident: 3180_CR6 publication-title: Mol Oncol doi: 10.1016/j.molonc.2010.04.006 – volume: 7 year: 2017 ident: 3180_CR25 publication-title: Sci Rep doi: 10.1038/s41598-017-05934-5 – volume: 130 start-page: 106263 year: 2023 ident: 3180_CR24 publication-title: Bioorg Chem doi: 10.1016/j.bioorg.2022.106263 – volume: 25 start-page: 1730 year: 2015 ident: 3180_CR35 publication-title: Bioorg Med Chem Lett doi: 10.1016/j.bmcl.2015.02.067 – volume: 16 start-page: 797 year: 2005 ident: 3180_CR9 publication-title: Anticancer Drugs doi: 10.1097/01.cad.0000173476.67239.3b – volume: 155 start-page: 113537 year: 2022 ident: 3180_CR41 publication-title: Biomed Pharmacother doi: 10.1016/j.biopha.2022.113537 – volume: 119 start-page: 2160 year: 2013 ident: 3180_CR2 publication-title: Cancer doi: 10.1002/cncr.28057 – volume: 7 start-page: 7155 year: 2022 ident: 3180_CR31 publication-title: ACS Omega doi: 10.1021/acsomega.1c06836 – volume: 57 start-page: 390 year: 2020 ident: 3180_CR27 publication-title: J Heterocycl Chem doi: 10.1002/jhet.3791 – volume: 3 start-page: 1 year: 2022 ident: 3180_CR17 publication-title: MedComm doi: 10.1002/mco2.163 – volume: 130 start-page: 2501 year: 2008 ident: 3180_CR20 publication-title: J Am Chem Soc doi: 10.1021/ja075523m – volume: 187 start-page: 1736 year: 2017 ident: 3180_CR8 publication-title: Am J Pathol doi: 10.1016/j.ajpath.2017.04.007 – volume: 7 start-page: 24858 year: 2022 ident: 3180_CR33 publication-title: ACS Omega doi: 10.1021/acsomega.2c03079 – volume: 5 start-page: 245 year: 2010 ident: 3180_CR14 publication-title: Target Oncol doi: 10.1007/s11523-010-0140-y – volume: 129 start-page: 106157 year: 2022 ident: 3180_CR42 publication-title: Bioorg Chem doi: 10.1016/j.bioorg.2022.106157 – volume: 31 start-page: 35 year: 2014 ident: 3180_CR16 publication-title: Nat Prod Rep doi: 10.1039/C3NP70058E |
| SSID | ssj0037045 |
| Score | 2.320569 |
| SecondaryResourceType | review_article |
| Snippet | Today, one of the most common malignancies in women is breast cancer. Despite the large number of commercially available anticancer drugs, cancer cannot be... |
| SourceID | proquest crossref springer |
| SourceType | Aggregation Database Enrichment Source Index Database Publisher |
| StartPage | 47 |
| SubjectTerms | 1-Phosphatidylinositol 3-kinase AKT protein Anticancer properties Antineoplastic drugs Antitumor agents Apoptosis Biochemistry Biomedical and Life Sciences Biomedicine Bioorganic Chemistry Breast cancer Cell death Cell proliferation Drugs Enzymatic activity Epidermal growth factor receptors Inorganic Chemistry Kinases Malignancy Medicinal Chemistry Pharmacology/Toxicology Review Article s-triazines Signal transduction Structure-activity relationships TOR protein Triazine |
| Title | A concise review on anti-breast cancer effectiveness of s-triazines through EGFR kinase inhibition |
| URI | https://link.springer.com/article/10.1007/s00044-023-03180-1 https://www.proquest.com/docview/2913117516 |
| Volume | 33 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3PT9swFH4a5cKFjTFER6neYeJCjeL8cnwsqAVtGkITldgpip1YVEUpIuFQ_vo9J06roTGJsx0rsT_7fS9-73sA32JDOCFTxjIhrai2LpiKZcYyT0lFBMTETfD4z-v4ahZ-v4vuXFJY1UW7d1eSzUm9TnZrLh8Z2Rhmgegx8nm2I57IpAfb48vfPybdCRwIrylOTNQhZD55Wi5Z5t-j_G2QNizz1cVoY2-mH2HWvWkbZrI4e67VmX55JeL43k_5BLuOgOK4RcwefCjKz3By0ypYr0Z4u0nIqkZ4gjcbbevVPqgxkgNtK3Fgm_SCyxJpccjDttHtNWqLoidsw0TcSYpLgxWz9UGslHWFrjYQTi6nv3AxL8mQ4ry8n6smfOwLzKaT24sr5so0ME37t2ZFLA05PYaHGdHFWAZRLmKeS6ON4YWSQZF5gQo0kQ_ywyOrty-0EnmSh77R9OQB9MplWRwCejLJqY0oiuZhLoRUnkqiIskVT3KTiD7wbq1S7TTMbSmNh3StvtxMbUpTmzZTm_I-nK6feWwVPP7be9BBIHW7uUp9aUWJRMTjPoy6Fd00vz3a1_d1P4IdnzhT-4dnAL366bk4Js5TqyFBfHp-fj10UB_C1swf_wF5tPd1 |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LSwMxEA6iB72IT6xWnYP0YgP7zuZYpLVqW4q00NuyyW6wKFvprof-eyfZ3RZFBc95HPIlmW-SmW8IuQkU7hM0ZTRmXItqy5SKgMc0tgQXSEBUYILHh6OgP_UeZ_6sSgrL62j3-kvS3NTrZDfz-UjRxlC9ES2KPs8OkoFQ1y2YOp36_nWZZUoTI3HwqIN-VpUq8_McX83RhmN--xY11qZ3QPYrmgidEtdDspVmR6Q1LnWmV22YbNKm8ja0YLxRoF4dE9EBdHN1vQwoU1NgkQEuIfrBOga9AKmxXkIZzFHdd7BQkFNdxUMLTudQVfCB7n3vGV7nGZo7mGcvc2GCvE7ItNed3PVpVUyBSjxlBU0DrtA1UbYXI6kLuOsnLLATrqRSdiq4m8aWK1yJFAG9ZV-r4jMpWBImnqMkjjwl29kiS88IWDxMsA2JhLS9hDEuLBH6aZgIO0xUyBrErtc0kpXSuC548RatNZINDhHiEBkcIrtBbtdj3kudjT97N2uoourM5ZHDtXQQ8-2gQdo1fJvm32c7_1_3a7LbnwwH0eBh9HRB9hxkOeWbTJNsF8uP9BJZSiGuzKb8BFOD2ws |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LS8QwEA6iIF7EJ67POche3GDTV5rjoru-ZREXvJUmaXBRuuLWg__eSdruqqjgOQ9oZjLzTTPzDSGHsUE9QVdGMy4sqbbKqYxFRjNPCokAxMQuefzmNj4fhpcP0cOnKn6X7d48SVY1DZalqSiPX7Q5nha-uYdIiv6GWqX0KMY_C2iOmdX0od9tbHHAPdemGEFESH2MueqymZ_3-OqaZnjz2xOp8zz9FbJcQ0boVjJeJXN5sUbag4pz-r0D97MSqkkH2jCYsVG_rxPZBfw22zsDqjIVGBeAx4kxsc1HL0FZub9CldhR2z4YG5hQ29HDkk9PoO7mA72z_h08jQp0fTAqHkfSJXxtkGG_d39yTuvGClThjStpHguDYYphYYYALxZBpHnMtDDKGJZLEeSZF8hAIVzAyDmyDPlcSa4THfpG4cpNMl-Mi3yLgCcSjWMIKhQLNedCejKJ8kRLlmiT8BZhzZmmqmYdt80vntMpX7KTQ4pySJ0cUtYiR9M1LxXnxp-zdxtRpfX9m6S-sDRCPGJxi3Qa8c2Gf99t-3_TD8ji4LSfXl_cXu2QJR8BT_V7ZpfMl69v-R4CllLuO538AC1E30c |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+concise+review+on+anti-breast+cancer+effectiveness+of+s-triazines+through+EGFR+kinase+inhibition&rft.jtitle=Medicinal+chemistry+research&rft.au=Tandel%2C+Pooja&rft.au=Upadhyay%2C+Rachana&rft.au=Patel%2C+Amit+B.&rft.date=2024-01-01&rft.pub=Springer+US&rft.issn=1054-2523&rft.eissn=1554-8120&rft.volume=33&rft.issue=1&rft.spage=47&rft.epage=65&rft_id=info:doi/10.1007%2Fs00044-023-03180-1&rft.externalDocID=10_1007_s00044_023_03180_1 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1054-2523&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1054-2523&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1054-2523&client=summon |